The first clear hint of targeted therapy's potential came in late 2003, when researchers at the German firm Boehringer Ingelheim reported that its hepatitis C protease inhibitor lowered the quantity of virus particles by roughly 99.9% in eight patients in two days of treatment, beating what interferon can accomplish in that time period.
FORBES: Magazine Article